Status:

RECRUITING

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

Lead Sponsor:

Takeda

Conditions:

Narcolepsy Type 2

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall a...

Eligibility Criteria

Inclusion

  • Key
  • The participant weighs greater than equal or to (≥)40 kilograms (kg) and has a body mass index (BMI) between 16 and 38 kilograms per meter square (kg/m\^2) \[inclusive\].
  • The participant has a documented, current diagnosis of NT2.
  • Key

Exclusion

  • The participant has a current medical disorder associated with excessive daytime sleepiness (EDS) other than NT2.
  • The participant has medically significant thyroid disease.
  • The participant has a history of cancer in the past 5 years. (This exclusion does not apply to participants with carcinoma in situ \[such as basal cell carcinoma\] that has been treated and is stable, or who have been stable without further treatment. These participants may be included after approval by the medical monitor).
  • The participant has any of the following viral infections based on a positive test result: Hepatitis B surface antigen (at screening), hepatitis C virus (HCV) antibody (at screening), human immunodeficiency virus (HIV) antibody/antigen (at screening).
  • The participant has a clinically significant history of head injury or head trauma.
  • The participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood).
  • The participant has a history of cerebral ischemia, transient ischemic attack (\<5 years from screening), intracranial aneurysm, or arteriovenous malformation.

Key Trial Info

Start Date :

May 6 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 23 2026

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06952699

Start Date

May 6 2025

End Date

April 23 2026

Last Update

November 3 2025

Active Locations (29)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (29 locations)

1

Takeda Site 14

Redwood City, California, United States, 94063-3132

2

Takeda Site 10

Santa Ana, California, United States, 92705-8519

3

Takeda Site 1

Colorado Springs, Colorado, United States, 80918-3408

4

Takeda Site 13

Brandon, Florida, United States, 33511-5719